Company Profile
Cerus Corporation Stock Price, News & Analysis
- Ticker:
- CERS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.32 USD (+2.20%)
Close
Last updated: August 6, 2026
541M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CERS closed up 2.20% at $2.32. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cerus is a blood-safety company focused on pathogen-reduction technology for platelets, plasma, and red blood cells. Its business is centered on making transfusions safer through a proprietary platform.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cerus sits in blood products and healthcare infrastructure.
Business Model Characteristics
The company depends on blood-center adoption, product utilization, and the expansion of pathogen-reduction systems.
Position Within the Biotechnology Landscape
Cerus is a niche transfusion-safety company that trades on adoption and operational execution rather than drug catalysts.
Future catalysts
Cerus’s next three months are about INTERCEPT Blood System adoption in platelets, plasma, and whole blood. The market will watch whether the company can keep converting blood-safety workflow into steady recurring demand.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cerus Corporation (CERS)?
Cerus Corporation (CERS) most recently closed at 2.32 USD, a +2.20% move versus the previous session.
What is the market cap of Cerus Corporation (CERS)?
Cerus Corporation currently has a market capitalization of 541M USD on BioPharmSignal.
What does Cerus Corporation do?
Cerus is a blood-safety company focused on pathogen-reduction technology for platelets, plasma, and red blood cells. Its business is centered on making transfusions safer through a proprietary platform.
On which exchange is CERS stock listed?
Cerus Corporation (CERS) is associated with NASDAQ, United States, Biopharma.
What is Cerus?
Cerus’s next three months are about INTERCEPT Blood System adoption in platelets, plasma, and whole blood.
Which conditions is Cerus Corporation targeting with Cerus?
Cerus’s next three months are about INTERCEPT Blood System adoption in platelets, plasma, and whole blood.
How does Cerus Corporation describe recent progress with Cerus?
Cerus’s next three months are about INTERCEPT Blood System adoption in platelets, plasma, and whole blood.
What is Blood?
Cerus is a blood-safety company focused on pathogen-reduction technology for platelets, plasma, and red blood cells.